Company Encyclopedia
View More
name
Clover Health Investments
CLOV.US
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It operates Clover Assistant, a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could.
418.03 B
CLOV.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
B
Managed Health CareIndustry
Industry Ranking7/9
Industry medianB
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-16.90%E
    • Profit Margin-3.29%D
    • Gross Margin14.73%D
  • Growth ScoreB
    • Revenue YoY32.15%A
    • Net Profit YoY36.18%B
    • Total Assets YoY-14.30%E
    • Net Assets YoY-0.36%C
  • Cash ScoreC
    • Cash Flow Margin-3041.04%E
    • OCF YoY32.15%A
  • Operating ScoreA
    • Turnover2.93A
  • Debt ScoreB
    • Gearing Ratio39.08%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Clover Corporation Sees 1HFY26 Revenue To Be In A Range Of A$40M - A$43M

    Clover Corporation Ltd :NOW EXPECTS 1HFY26 REVENUE TO BE IN A RANGE OF A$40M - A$43MEXPECT FULL YEAR REVENUE SHOULD OUTPERFORM FY25

    Reuters·
    US
    CLOV
    -6.90%
    Reuters·
    US
    CLOV
    -6.90%

    Clover Health Investments Corp. to Present at Citi Global Healthcare Conference

    Clover Health Investments Corp. will present at the 2025 Citi Global Healthcare Conference, with CFO Peter Kuipers speaking on December 4, 2025. The presentation will be webcast live and available for replay on the company's investor relations website. This announcement was originally published via GlobeNewswire.

    Reuters·
    US
    CLOV
    -6.90%
    Reuters·
    US
    CLOV
    -6.90%

    Clover Health Addresses Shareholder Concerns Post Q3 Earnings

    Clover Health Investments (CLOV) addressed shareholder concerns following its Q3 2025 earnings announcement, revealing increased medical costs impacting margins. Despite challenges, the company is optimistic about 2026, citing favorable updates and enhanced Clover Assistant coverage. Analysts rate CLOV stock as a Buy with a $3.70 target, though Spark's AI Analyst considers it Neutral due to ongoing financial issues. Clover Health focuses on Medicare Advantage plans and aims to improve profitability and customer service. Current market cap stands at $1.34B with an average trading volume of 8,857,060.

    Tip Ranks·
    US
    CLOV
    -6.90%
    Tip Ranks·
    US
    CLOV
    -6.90%

    Clover Health Investments | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 496.65 B

    LB filings·
    US
    CLOV
    -6.90%
    LB filings·
    US
    CLOV
    -6.90%

    Clover Health (CLOV) Price-to-Sales Discount Challenges Skeptics as Profitability Forecast Strengthens

    Clover Health (CLOV) is currently unprofitable but has reduced losses by 25.5% annually over five years. Revenue is expected to grow at 14.9% per year, with earnings projected to surge by 77.48% annually, leading to anticipated profitability within three years. The company's Price-to-Sales Ratio of 0.9x is lower than peers, indicating a value opportunity. However, risks include share price volatility and reliance on Medicare, which could impact revenue and margins. Analysts have a price target of $3.37, suggesting potential upside from current levels.

    Simplywall·
    US
    CLOV
    -6.90%
    Simplywall·
    US
    CLOV
    -6.90%